astma

2 trials

Sponsors

Novartis

Conditions

asthma N/Aasthma chronic lung inflammation

Phase 2

A randomized, double-blind, repeat dose cross-over study to assess the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 days compared to placebo in patients with asthma

Active, not recruitingNL-OMON44320

Novartisasthma chronic lung inflammation

Start: 2017-06-22Target: 20Updated: 2024-02-28

Phase 3

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

RecruitingNL-OMON53380

Novartisasthma N/A

Start: 2016-03-11Target: 15Updated: 2024-02-28